A clinical phase I trial studying an AhR inhibitor in patients with advanced small cell lung cancer or head and neck cancer has recently been completed (NCT04069026), highlighting that AhR merits further investigation in the cancer setting. The gene discussed is AHR; the disease is small cell lung carcinoma.